BUGA-CoL Undenatured Type II Collagen From Chicken Sternum, Lyophilized
BUGA-CoL Undenatured Type II Collagen From Chicken Sternum (BUGA-UCOLL-II) is derived from chicken sternum cartilage obtained from certified organizations that comply with the Turkish Food Codex, food safety, and quality standards. BUGA-UCOLL-II is produced under GMP conditions and is a medical-grade, water-soluble, undenatured Type II collagen.
BUGA-UC-II is obtained by lyophilizing the solution extracted from chicken cartilage, resulting in a white powder form. Since the processes are carried out at low temperatures, the Type II collagen remains undenatured, preserving its 3D helical structure. BUGA-UCOLL-II has a neutral pH, making it compatible with the digestive system. The recommended daily dose is 40 mg. BUGA-UCOLL-II supports joint health, promotes cartilage repair, and enhances ease of movement. By improving mechanical resistance between joints, it prevents friction and wear of bone tissues.
• Biomaterial Design
• Joint Health
• Osteoarthritis Treatment
• Cartilage Repair
• Food Supplements
• Inflammation Reduction
1. Accurately weigh the desired amount of BUGA-UCOLL-II product and dissolve it in pure water.
2. Add the prepared BUGA-UCOLL-II solution to your formulation in desired amounts and concentrations. Ensure the mixture is homogeneous.
3. To maintain the freshness of the solution, store it at +4 ºC, i.e., in a refrigerator.
4. Note: For food supplements, a daily dose of 40 mg is generally recommended. You can use it considering this suggested dosage.
Product Technical Specifications
Appearance | Lyophilized white powder |
Smell | No data available |
Extraction method | Collagen without enzymatic modification |
Resolution | Pure water |
Storage temperature | 2-8 ºC |
Shelf life | 2 years from date of production |
Solution shelf life | 3 ay (+4 ºC’de) |
Source (Animal type) | Chicken Sternum |
SDS PAGE (molecular weight and impurity determination) | α chains formed at the level of 100-135 kDa and β chains formed at the level of 245 kDa are seen. |
• Harris, R. B., Fonseca, F. L. A., Sharp, M. H., & Ottinger, C. R. (2022). Functional characterization of undenatured type II collagen supplements: Are they interchangeable? Journal of dietary supplements, 19(6), 717-732.
• Kumar, P., Bansal, P., Rajnish, R. K., Sharma, S., Dhillon, M. S., Patel, S., & Kumar, V. (2023). Efficacy of undenatured collagen in knee osteoarthritis: review of the literature with limited meta-analysis. American Journal of Translational Research, 15(9), 5545.
• Luo, C., Su, W., Song, Y., & Srivastava, S. (2022). Efficacy and safety of native type II collagen in modulating knee osteoarthritis symptoms: a randomised, double‐blind, placebo‐controlled trial. Journal of Experimental Orthopaedics, 9(1), 123.
• Wang, H. (2021). A review of the effects of collagen treatment in clinical studies. Polymers, 13(22), 3868.
• Yoshinari, O., Moriyama, H., & Shiojima, Y. (2015). An overview of a novel, water-soluble undenatured type II collagen (NEXT-II). Journal of the American College of Nutrition, 34(3), 255-262.
• Zhou, Y., Zhang, Y., Dai, H., Zhang, Y., & Fu, Y. (2024). The potential of undenatured type II collagen against arthritis: a review. Collagen and Leather, 6(1), 17.
